Trials | Treatment | Duration of follow up (years) | Events avoided per 1000 patients treated* | ||
---|---|---|---|---|---|
Deaths | Acute MI | Heart failure | |||
*Events avoided relates to the number of patients avoiding event; more episodes than this were avoided—for example, there were 43 fewer hospital admissions for heart failure per 1000 patients treated with eplerenone (as opposed to 14 fewer patients hospitalised for heart failure). Note: (1) Different duration of follow up; deaths avoided per 1000 patient years would be: 22 with an ACE inhibitor, 26 with a β blocker, 18 with an aldosterone blocker. (2) Events are not mutually exclusive; for the composite of death or acute MI, 66 fewer patients per 1000 treated experienced this composite with an ACE inhibitor and 53 fewer with a β blocker; for death, MI, or heart failure the number was 69 with an ACE inhibitor. | |||||
SAVE, AIRE, TRACE meta-analysis | ACE inhibitor | 2.6 | 57 | 23 | 36 |
CAPRICORN | β Blocker | 1.3 | 34 | 23 | – |
EPHESUS | Aldosterone blocker | 1.3 | 23 | – | 14 |